Real-world data show that the administration of thrombopoietin receptor agonists in immune thrombocytopenia leads to a high percentage of treatment responses, and in some patients, it is possible to achieve a stable response without the need for further treatment after discontinuation.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
